Scholarlink

<p>Acquired pure red cell aplasia (PRCA) affects only the red blood cell lineage and responds to immunosuppressive therapy. Few reports describe the outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for refractory PRCA. This study investigated the outcomes of allo-HSCT for PRCA using Japanese nationwide registry data. Eight patients aged 16&#xa0;years or older who underwent allo-HSCT for acquired PRCA were analyzed. Median ages at diagnosis of PRCA and HSCT were 39.5 (range 19–68) and 47.5 (range 21–68) years, respectively. Stem cell sources and donors were bone marrow (related, <i>n</i> = 2; unrelated, <i>n</i> = 3), umbilical cord blood (<i>n</i> = 2), and peripheral blood stem cells (related, <i>n</i> = 1). All patients achieved neutrophil engraftment with a median time to engraftment of 21&#xa0;days. Four patients died within 3&#xa0;months after HSCT; the causes of death were acute myocardial infarction, thrombotic microangiopathy, capillary leak syndrome, and bacterial pneumonia. The remaining four patients were alive and transfusion-independent at a median follow-up of 99.4&#xa0;months (range 21–148). Allo-HSCT could be a curative treatment option for refractory PRCA. However, early post-transplant mortality is an obstacle, and thus, optimal transplant procedures should be carefully determined for each patient.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Outcomes of allogeneic hematopoietic stem cell transplantation for acquired pure red cell aplasia

  • 期刊论文

  • 发表日期：

    2025年12月22日

查看全文
  • Yuma Noguchi,
  • Takehiko Mori,
  • Yasushi Onishi,
  • Yukinori Nakamura,
  • Minoru Kanaya,
  • Shinichi Ito,
  • Kosei Matsue,
  • Shingo Yano,
  • Makoto Onizuka,
  • Tetsuya Nishida,
  • Seitaro Terakura,
  • Satoshi Yoshihara,
  • Takeshi Maeda,
  • Tatsuo Ichinohe,
  • Yoshiko Atsuta,
  • Katsuto Takenaka

摘要

Acquired pure red cell aplasia (PRCA) affects only the red blood cell lineage and responds to immunosuppressive therapy. Few reports describe the outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for refractory PRCA. This study investigated the outcomes of allo-HSCT for PRCA using Japanese nationwide registry data. Eight patients aged 16 years or older who underwent allo-HSCT for acquired PRCA were analyzed. Median ages at diagnosis of PRCA and HSCT were 39.5 (range 19–68) and 47.5 (range 21–68) years, respectively. Stem cell sources and donors were bone marrow (related, n = 2; unrelated, n = 3), umbilical cord blood (n = 2), and peripheral blood stem cells (related, n = 1). All patients achieved neutrophil engraftment with a median time to engraftment of 21 days. Four patients died within 3 months after HSCT; the causes of death were acute myocardial infarction, thrombotic microangiopathy, capillary leak syndrome, and bacterial pneumonia. The remaining four patients were alive and transfusion-independent at a median follow-up of 99.4 months (range 21–148). Allo-HSCT could be a curative treatment option for refractory PRCA. However, early post-transplant mortality is an obstacle, and thus, optimal transplant procedures should be carefully determined for each patient.